Approved HBV Drugs
Approved HBV Drugs
No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Friday, 27 June 2014 00:00
- Written by Liz Highleyman
No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in the June 11 advance edition of Clinical Gastroenterology and Hepatology. Adding emtricitabine (Emtriva) did not improve effectiveness compared with tenofovir alone.
AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years
- Details
- Category: HBV Treatment
- Published on Wednesday, 04 December 2013 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.
AASLD 2013: Hepatitis B Treatment with Entecavir or Tenofovir Lowers, But Does Not Eliminate, HCC Risk
- Details
- Category: HBV Treatment
- Published on Wednesday, 06 November 2013 00:00
- Written by Liz Highleyman
Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B virus (HBV) infection will develop hepatocellular carcinoma, according to findings presented this week at the 64thAASLD Liver Meeting in Washington, DC. Another study, however, found that while entecavir or tenofovir can reduce the risk, people with hepatitis B should continue to undergo regular monitoring for liver cancer, and better predictive models may be needed for Caucasian patients.
AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Published on Monday, 11 November 2013 00:00
- Written by Liz Highleyman
A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC.
IDWeek 2013: Entecavir and Tenofovir Both Work Well Against Hepatitis B in Clinical Practice
- Details
- Category: HBV Treatment
- Published on Tuesday, 15 October 2013 00:00
- Written by Liz Highleyman
Entecavir (Baraclude) and tenofovir (Viread) both demonstrated potent activity against hepatitis B virus (HBV) in a Turkish study presented at the second IDWeek conference held recently in San Francisco. Entecavir appeared to have an edge with regard to hepatitis B "e" antigen (HBeAg) seroconversion, but this rose with time among people taking either drug.
More Articles...
- DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?
- DDW 2013: Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus
- Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients
Web Design and Development by